November 17, 2021 -- Memorial Sloan Kettering Cancer Center has agreed to allow its next generation signaling technology 1XX to be used in Abintus Bio's in vivo CAR X products.
The products have the potential to improve outcomes for patients with hematologic malignancies and solid tumors while overcoming the challenges of ex vivo CAR technologies, according to Abintus Bio. Currently, 1XX CARs are under clinical evaluation in multiple cancers.
In vivo CAR X products aim to simultaneously target both adaptive and innate immune effector cells, including active T cells and NK cells, to produce an immune response against hematologic malignancies and solid tumors.
Abintus' initial products targeting hematologic and solid tumors are poised to enter clinical evaluation in early 2023.